Related Experiment Video
Updated: Jul 14, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Therapeutic issues in HIV/HCV-coinfected patients
1Department of Medicine, Division of Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, MD 21287-0003, USA. msulkows@jhmi.edu
Journal of Viral Hepatitis
|May 16, 2007
Summary
Treating hepatitis C virus (HCV) in patients with human immunodeficiency virus (HIV) is crucial. Combination therapy slows liver fibrosis but managing toxicities like anemia and hepatotoxicity is essential for effective treatment.
Area of Science:
- Hepatology
- Infectious Diseases
- Virology
Background:
- The advent of highly active antiretroviral therapy has increased the focus on managing hepatitis C virus (HCV) comorbidities in coinfected patients with human immunodeficiency virus (HIV).
- HIV/HCV coinfection is associated with higher HCV RNA levels and accelerated liver fibrosis progression compared to HCV monoinfection.
- Managing HCV in HIV-coinfected individuals presents unique challenges, including increased risk of hepatotoxicity, anemia, and drug-drug interactions.
Purpose of the Study:
- To review the current literature and expert opinions on treating chronic hepatitis C in HIV-coinfected patients.
- To address the complexities of HCV treatment in the context of HIV coinfection, focusing on efficacy and toxicity.
- To present recommendations from the European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-infected Patients.
Main Methods:
- Systematic review of peer-reviewed literature published between 1990 and 2005.
- Inclusion of expert opinion and consensus conference findings.
- Comparative analysis of treatment outcomes and challenges in coinfected patients.
Main Results:
- Combination therapy with pegylated interferon and ribavirin (RBV) is the standard for HCV treatment in coinfected patients.
- While this therapy slows fibrosis, dose-limiting toxicities, including hepatotoxicity and anemia, complicate treatment.
- HIV/HCV-coinfected patients face a threefold higher risk of antiretroviral therapy-associated hepatotoxicity.
Conclusions:
- Chronic hepatitis C must be treated in HIV/HCV-coinfected patients.
- Preventive and therapeutic strategies for managing treatment-related toxicities are critical for successful outcomes.
- Addressing coinfection challenges requires a multidisciplinary approach and adherence to consensus guidelines.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:26Sexually Transmitted Infections
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.